Lisa Polin

4.0k total citations
102 papers, 3.0k citations indexed

About

Lisa Polin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lisa Polin has authored 102 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 30 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lisa Polin's work include Cancer therapeutics and mechanisms (14 papers), Folate and B Vitamins Research (11 papers) and Histone Deacetylase Inhibitors Research (10 papers). Lisa Polin is often cited by papers focused on Cancer therapeutics and mechanisms (14 papers), Folate and B Vitamins Research (11 papers) and Histone Deacetylase Inhibitors Research (10 papers). Lisa Polin collaborates with scholars based in United States, China and Saudi Arabia. Lisa Polin's co-authors include Juiwanna Kushner, Kathryn White, Thomas H. Corbett, Jerome P. Horwitz, Eduardo Palomino, Stuart Hazeldine, Larry H. Matherly, Zhanjun Hou, Aleem Gangjee and Arun K. Rishi and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Blood.

In The Last Decade

Lisa Polin

101 papers receiving 2.9k citations

Peers

Countries citing papers authored by Lisa Polin

Since Specialization

Citations

This map shows the geographic impact of Lisa Polin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Polin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Polin more than expected).

Fields of papers citing papers by Lisa Polin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Polin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Polin. The network helps show where Lisa Polin may publish in the future.

Co-authorship network of co-authors of Lisa Polin

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Polin. A scholar is included among the top collaborators of Lisa Polin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Polin. Lisa Polin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress 2025 ·Journal of Experimental & Clinical Cancer Research ·Jenna L. Carter, Yongwei Su, (unknown), Jianlei Zhao, (unknown), Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, (unknown), Kathryn White, Steven Buck, Maik Hüttemann, Joshua E. Allen, (unknown), Jay Yang, Jeffrey W. Taub, Yubin Ge	0
2	Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia 2024 ·Blood ·(unknown), Md. Hafiz Uddin, (unknown), (unknown), Amro Aboukameel, Husain Yar Khan, (unknown), Jay Yang, Gregory Dyson, Steven Buck, Asfar S. Azmi, Lisa Polin, Francis Burrows, Linda Kessler, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian	2
3	ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe 2023 ·NAR Cancer ·Joshua Heyza, (unknown), (unknown), (unknown), Christopher K. Yunker, (unknown), (unknown), Lisa Polin, (unknown), Eric Van Buren, Donovan Watza, (unknown), Wei Chen, Hirva Mamdani, Ann G. Schwartz, John J. Turchi, Gerold Bepler, Steve M. Patrick	4
4	The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML 2021 ·Blood Cancer Journal ·(unknown), Jun Ma, Tristan Knight, Yongwei Su, Holly Edwards, Lisa Polin, Jing Li, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jian Wang, Hai Lin, Yue Wang, (unknown), Guan Wang, Jeffrey W. Taub, Yubin Ge	27
5	Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia 2020 ·Signal Transduction and Targeted Therapy ·Daniel A Luedtke, Yongwei Su, Jun Ma, Xinyu Li, Steven Buck, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Hai Lin, Jeffrey W. Taub, Yubin Ge	50
6	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation 2020 ·Cancers ·Fangbing Liu, Hasini A. Kalpage, (unknown), Holly Edwards, Maik Hüttemann, Jun Ma, Yongwei Su, Jenna L. Carter, Xinyu Li, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Guan Wang, Jeffrey W. Taub, Yubin Ge	29
7	The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53 2020 ·Cell Death and Disease ·Hu Chen, Mu Zhang, (unknown), (unknown), Lisa Polin, Wei Chen, Hyejeong Jang, Joshua Heyza, (unknown), Joseph A. Caruso, Shengyan Xiang, Steve M. Patrick, Paul M. Stemmer, Zhenkun Lou, Wenlong Bai, Chuangui Wang, Gerold Bepler, (unknown)	48
8	Antagonizing binding of cell cycle and apoptosis regulatory protein 1 (CARP-1) to the NEMO/IKKγ protein enhances the anticancer effect of chemotherapy 2020 ·Journal of Biological Chemistry ·(unknown), Sreeja C. Sekhar, Vino T. Cheriyan, Magesh Muthu, (unknown), Edi Levi, (unknown), James W. Gauld, Lisa Polin, Arun K. Rishi	4
9	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia 2019 ·Clinical Cancer Research ·Jun Ma, (unknown), (unknown), Tristan Knight, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Guan Wang, Lijing Zhao, Hai Lin, Yue Wang, Jeffrey W. Taub, Yubin Ge	117
10	Nano-delivery of RAD6 /Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy 2018 ·Molecular Cancer Therapeutics ·Nadia Saadat, Fangchao Liu, Brittany Haynes, Pratima Nangia‐Makker, Xun Bao, Jing Li, Lisa Polin, Smiti Gupta, Guangzhao Mao, Malathy P.V. Shekhar	15
11	Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer 2018 ·Clinical Cancer Research ·Rayna Rosati, Lisa Polin, Charles Ducker, Jing Li, Xun Bao, (unknown), Seongho Kim, (unknown), Martha J. Larsen, (unknown), Yanfang Huang, Benjamin L. Kidder, Andrew M. Fribley, Janice Saxton, Hiroki Kakuta, Peter E. Shaw, Manohar Ratnam	16
12	Using Radiolabeled 3′-Deoxy-3′-¹⁸F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non–Small Cell Lung Cancer 2018 ·Journal of Nuclear Medicine ·(unknown), (unknown), Jawana M. Lawhorn‐Crews, Lisa Polin, Shirish M. Gadgeel, (unknown), Thomas J. Mangner, Kirk Douglas, Jing Li, Manohar Ratnam, Anthony F. Shields	9
13	Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor 2018 ·Scientific Reports ·(unknown), (unknown), Rayna Rosati, Yanfang Huang, (unknown), Lisa Polin, (unknown), Mike R. Wilson, Fulvio Lonardo, (unknown), Jing Li, Larry H. Matherly, Gerold Bepler, Manohar Ratnam	10
14	Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3- d ]pyrimidine Antifolates 2017 ·Molecular Cancer Therapeutics ·Zhanjun Hou, (unknown), (unknown), Yang Si, Adrianne Wallace-Povirk, (unknown), (unknown), Lisa Polin, Kathryn White, Juiwanna Kushner, Robert Morris, Aleem Gangjee, Larry H. Matherly	38
15	Correction: Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo 2013 ·PLoS ONE ·Huanjie Yang, Ying Wang, (unknown), Wenjuan Wu, (unknown), Lisa Polin, Harvey I. Pass, Q. Ping Dou, Arun K. Rishi, Anil Wali	1
16	Functional Loss of the Reduced Folate Carrier Enhances the Antitumor Activities of Novel Antifolates with Selective Uptake by the Proton-Coupled Folate Transporter 2012 ·Molecular Pharmacology ·Sita Kugel Desmoulin, Lei Wang, Lisa Polin, Kathryn White, Juiwanna Kushner, Mark Stout, Zhanjun Hou, Christina Cherian, Aleem Gangjee, Larry H. Matherly	27
17	Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor 2010 ·Cancer Chemotherapy and Pharmacology ·Edi Levi, Liyue Zhang, Amro Aboukameel, (unknown), Ramzi M. Mohammad, Lisa Polin, James S. Hatfield, Arun K. Rishi	4
18	The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms 2008 ·Cancer Research ·April L. Risinger, Evelyn M. Jackson, Lisa Polin, Gregory L. Helms, (unknown), (unknown), Elizabeth Hopper-Borge, Richard F. Ludueña, Gary D. Kruh, Susan L. Mooberry	111
19	Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs 1996 ·Pharmaceutical Research ·Elaine Merisko‐Liversidge, Pramod P. Sarpotdar, Joseph G. Bruno, (unknown), Liang Wei, (unknown), James Rake, Jyoti Shaw, Susan Pugh, Lisa Polin, Julie Jones, Thomas H. Corbett, Eugene R. Cooper, Gary G. Liversidge	174
20	Comparative efficacy of DMP 840 against mouse and human solid tumor models 1995 ·Investigational New Drugs ·Patricia LoRusso, Lisa Demchik, Maria Dan, Lisa Polin, Janet L. Gross, Thomas H. Corbett	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact